Quarterly report pursuant to Section 13 or 15(d)

Acquisition of patents and Intangibles - Additional Information (Detail)

v3.10.0.1
Acquisition of patents and Intangibles - Additional Information (Detail) - USD ($)
 3 Months Ended 6 Months Ended
Oct. 16, 2012
Nov. 30, 2018
Nov. 30, 2017
Nov. 30, 2018
Nov. 30, 2017
May 31, 2018
Acquired Finite-Lived Intangible Assets [Line Items]            
Intangible asset acquired gross   $ 3,500,000   $ 3,500,000    
Issuance of common stock shares   290,808,960   290,808,960   216,881,790
Common stock per shares   $ 0.001   $ 0.001   $ 0.001
Estimated aggregate future amortization expense in next twelve months   $ 1,600,000   $ 1,600,000    
Estimated aggregate future amortization expense in year two   1,600,000   1,600,000    
Estimated aggregate future amortization expense in year three   1,600,000   1,600,000    
Estimated aggregate future amortization expense in year four   1,600,000   1,600,000    
Estimated aggregate future amortization expense in year five   1,600,000   1,600,000    
ProstaGene, LLC            
Acquired Finite-Lived Intangible Assets [Line Items]            
Acquisition of ProstaGene LLC, value   $ 11,558,000   $ 11,558,000    
Issuance of common stock shares   20,278,000   20,278,000    
Common stock per shares   $ 0.57   $ 0.57    
ProstaGene, LLC | Dr .Pestell | Stock Restriction Agreement            
Acquired Finite-Lived Intangible Assets [Line Items]            
Restricted common stock, shares   8,342,000   8,342,000    
Common stock shares restriction period       3 years    
Stock repurchase price, per share       $ 0.001    
Investment Advisory, Management and Administrative Service [Member] | ProstaGene, LLC            
Acquired Finite-Lived Intangible Assets [Line Items]            
Investment earned shares   1,620,000   1,620,000    
Patents            
Acquired Finite-Lived Intangible Assets [Line Items]            
Asset purchase, cash paid $ 3,500,000          
Estimated useful life of acquired asset 10 years          
Amortization expense related to acquired patents   $ 152,900 $ 87,500 $ 240,400 $ 175,000